Chemotherapy-induced Alopecia
12
4
5
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (12)
Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads)
Effect of Helmet Type, Home-use Low-level Light Therapy Device for Chemotherapy-induced Alopecia
Prevention of Alopecia in Patients With Localised Breast Cancer
Scalp Cooling in MBC
Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Chemotherapy-Induced Alopecia
Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss
Photobiomodulation Therapy in the Prevention and Management of Chemotherapy-Induced Alopecia
Study To Evaluate The Efficacy And Safety Profile of ECOHAIR in Chemo-induced Alopecia.
A Pilot Study to Evaluate the Use of the AMMA Portable Scalp Cooling System From Cooler Heads
PBMT for the Management of CIA ( HAIRLASER )
Efficacy and Safety of DIGNICAP™ System
"Impact of Chemotherapy-induced Alopecia on the Quality of Life of Women With Breast Cancer"